A significantly greater proportion of patients in the enzalutamide group than in the placebo group reported clinically meaningful improvements in FACT-P total score ( @ -LSB- @ % -RSB- of @ vs @ -LSB- @ % -RSB- of @ ) , in EQ-@D utility index ( @ -LSB- @ % -RSB- of @ vs @ -LSB- @ % -RSB- of @ ) , and visual analogue scale ( @ -LSB- @ % -RSB- of @ vs @ of -LSB- @ % -RSB- @ ; all p < @ ) .